Novartis: acquisition of US-based Mariana Oncology
Novartis, which is seeking to strengthen its position in innovative cancer treatments, will initially pay an initial amount of $1 billion, to which could be added additional payments of $750 million, the Basel-based laboratory said in a press release.
Mariana Oncology, a biotech company based in Watertown (Massachusetts), specializes in radioligand therapies (RLT) to cure cancers for which there is no effective treatment yet.
The company's lead drug candidate, MC-339, is currently being developed for the treatment of small-cell lung cancer.
Novartis itself has a portfolio of two radioligand-targeted therapies, for prostate cancer and gastrointestinal neuroendocrine tumors.
Radioligand treatments are precision cancer therapies that combine a targeting compound (ligand) and a therapeutic radioisotope (radioactive particle).
The market greeted the news without euphoria, as Novartis shares were perfectly stable on the Zurich stock exchange on Thursday.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction